ONCAlert | Upfront Therapy for mRCC

Gynecologic Cancers VIEW MORE >>

In an interview with Targeted Oncology, Eric Pujade-Lauraine, MD, PhD, discussed the data from the JAVELIN Ovarian 200 trial, which he presented at the 2019 SGO Annual Meeting. He highlighted the need for biomarkers in this space, as well as some data from an exploratory analysis from this trial.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.